Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Oncopeptides has announced an exclusive distribution and commercialization agreement with Salus for its multiple myeloma drug, Pepaxti, covering 11 countries in Central and Eastern Europe (CEE).</li><li>This leverages a local partner to unlock a region with an estimated total market potential of SEK150m, driving geographic expansion ahead of the company’s original internal timeline.</li></ul>

Oncopeptides has announced an exclusive distribution and commercialization agreement with Salus for its multiple myeloma drug, Pepaxti, covering 11 countries in Central and Eastern Europe (CEE).This leverages a local partner to unlock a region with an estimated total market potential of SEK150m, driving geographic expansion ahead of the company’s original internal timeline.

Oncopeptides: Expands Pepaxti Footprint into CEE Region via Salus Partnership